MA52416A - Anticorps b7-h4 et leurs procédés d'utilisation - Google Patents

Anticorps b7-h4 et leurs procédés d'utilisation

Info

Publication number
MA52416A
MA52416A MA052416A MA52416A MA52416A MA 52416 A MA52416 A MA 52416A MA 052416 A MA052416 A MA 052416A MA 52416 A MA52416 A MA 52416A MA 52416 A MA52416 A MA 52416A
Authority
MA
Morocco
Prior art keywords
antibodies
processes
Prior art date
Application number
MA052416A
Other languages
English (en)
Inventor
Majid Ghoddusi
Charles Kaplan
Nerissa Mendoza
Kathy Miller
Alessandro Palumbo
Hangil Park
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MA52416A publication Critical patent/MA52416A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052416A 2018-03-02 2019-03-01 Anticorps b7-h4 et leurs procédés d'utilisation MA52416A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862637740P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
MA52416A true MA52416A (fr) 2021-04-21

Family

ID=65763883

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052416A MA52416A (fr) 2018-03-02 2019-03-01 Anticorps b7-h4 et leurs procédés d'utilisation

Country Status (14)

Country Link
US (1) US11939383B2 (fr)
EP (1) EP3759142A1 (fr)
JP (2) JP2021516051A (fr)
KR (1) KR20200144094A (fr)
CN (1) CN111971308A (fr)
AU (1) AU2019228600A1 (fr)
BR (1) BR112020017925A2 (fr)
CA (1) CA3091801A1 (fr)
EA (1) EA202091810A1 (fr)
IL (1) IL276790A (fr)
MA (1) MA52416A (fr)
MX (1) MX2020009037A (fr)
SG (1) SG11202008105RA (fr)
WO (1) WO2019169212A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094352A (zh) 2017-08-25 2020-05-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法
JP7393337B2 (ja) * 2018-02-11 2023-12-06 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
EA202091747A1 (ru) * 2018-02-21 2021-02-10 Файв Прайм Терапьютикс, Инк. Составы антитела b7-h4
CA3091801A1 (fr) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. Anticorps b7-h4 et leurs procedes d'utilisation
JP2024511465A (ja) 2021-03-26 2024-03-13 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
AU2022288123A1 (en) 2021-06-09 2023-11-30 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a
WO2022258691A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a
AU2022358522A1 (en) * 2021-09-30 2024-03-28 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US7328387B2 (en) 2004-12-10 2008-02-05 Texas Instruments Incorporated Addressable tap domain selection circuit with selectable ⅗ pin interface
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP0733070A1 (fr) 1993-12-08 1996-09-25 Genzyme Corporation Procede de generation d'anticorps specifiques
WO1995020401A1 (fr) 1994-01-31 1995-08-03 Trustees Of Boston University Banques d'anticorps polyclonaux
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US20030181692A1 (en) 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (fr) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
WO2002016429A2 (fr) 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
SE9804180L (sv) 1998-12-03 2000-01-24 Scania Cv Ab Anordning för ventilation av ett utrymme i ett fordon
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
CA2359067C (fr) 1999-01-15 2017-03-14 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2264166B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
CA2388245C (fr) 1999-10-19 2012-01-10 Tatsuya Ogawa L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
WO2001040269A2 (fr) 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US20040142361A1 (en) 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20020146727A1 (en) 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
AU2001245308A1 (en) 2000-02-24 2001-09-03 Human Genome Sciences, Inc. 207 human secreted proteins
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
EP1301524A1 (fr) 2000-06-30 2003-04-16 Human Genome Sciences, Inc. Polynucl otides du type b7, polypeptides et anticorps en rapport
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2002016581A2 (fr) 2000-08-24 2002-02-28 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement de tumeurs
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004006955A1 (fr) 2001-07-12 2004-01-22 Jefferson Foote Anticorps super humanises
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2005062788A2 (fr) 2003-12-22 2005-07-14 Avalon Pharmaceuticals, Inc. Proteines specifiques de la prostate exprimees dans le cancer et methodes d'utilisation associees
US20060166212A1 (en) 2002-12-20 2006-07-27 Bernd Weigle Breast specific protein expressed in cancer and methods of use thereof
US20050287147A1 (en) 2002-05-15 2005-12-29 Reinhard Ebner Cancer-linked gene as target for chemotherapy
WO2005035724A2 (fr) 2003-10-08 2005-04-21 Avalon Pharmaceuticals, Inc Genes lies au cancer en tant que cibles de chimiotherapie
AU2003213743A1 (en) 2002-03-06 2003-09-22 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
NZ534880A (en) 2002-03-19 2008-04-30 Plant Res Int Bv Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CA2485981A1 (fr) 2002-05-16 2003-11-27 Avalon Pharmaceuticals Gene lie au cancer utilise comme cible pour la chimiotherapie
AU2003239969A1 (en) 2002-06-04 2003-12-19 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003249691A1 (en) 2002-06-07 2003-12-22 Avalon Pharmaceuticals, Inc Cancer-linked gene as target for chemotherapy
CA2489198A1 (fr) 2002-06-11 2003-12-18 Avalon Pharmaceuticals, Inc. Genes lies au cancer servant de cibles de chimiotherapie
WO2007001459A2 (fr) 2004-11-15 2007-01-04 Washington University Compositions et procedes pour moduler l'activite lymphocytaire
CA2489803A1 (fr) 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions et procedes de modulation de l'activite lymphocytaire
JP5425365B2 (ja) 2003-01-22 2014-02-26 グリカート バイオテクノロジー アクチェンゲゼルシャフト 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用
ATE516047T1 (de) 2003-05-09 2011-07-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und anwendungsverfahren
WO2004113500A2 (fr) 2003-06-16 2004-12-29 The University Of Washington B7s1: modulateur immun
WO2005052121A2 (fr) 2003-11-21 2005-06-09 Archemix Corp. Aptameres multivalents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1817055B1 (fr) 2004-11-10 2012-12-26 Diadexus, Inc. Compositions d'anticorps anti-ovr110 et methodes d'utilisation correspondantes
DE602006013275D1 (de) 2005-01-07 2010-05-12 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
US20090118175A1 (en) 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
WO2007039818A2 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
CA3201163A1 (fr) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
SG170080A1 (en) 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
WO2007082154A2 (fr) 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4
EP1974040B1 (fr) 2006-01-17 2012-10-03 Biolex Therapeutics, Inc. Compositions et procédés d'humanisation et optimisation de N-glycanes chez les plantes
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
US9121853B2 (en) * 2006-03-20 2015-09-01 Mayo Foundation For Medical Education And Research B7-H4 expression on tumor vasculature
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2007124361A2 (fr) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research B7-h1 soluble
WO2008051919A2 (fr) 2006-10-23 2008-05-02 Acco Brands Usa Llc Appareil de sécurité
CA2670696A1 (fr) 2006-11-27 2008-06-05 Diadexus, Inc. Compositions d'anticorps ovr110 et leurs procedes d'utilisation
EP2102241A2 (fr) 2006-12-15 2009-09-23 Ablynx N.V. Séquences d'acides aminés qui modulent l'interaction entre des cellules du système immunitaire
JP2011502954A (ja) 2006-12-27 2011-01-27 ザ ジョンズ ホプキンス ユニバーシティー 免疫応答を刺激する組成物および方法
WO2008154333A2 (fr) 2007-06-08 2008-12-18 Asuragen, Inc. Gènes et chemins régulés par mir-34 en tant que cibles pour une intervention thérapeutique
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX2010002661A (es) 2007-09-14 2010-05-20 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
WO2009073533A2 (fr) 2007-11-30 2009-06-11 Medarex, Inc. Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
WO2009111315A2 (fr) 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Méthodes de réduction de l’inflammation granulomateuse
WO2011020024A2 (fr) 2009-08-13 2011-02-17 The Johns Hopkins University Méthodes de modulation de la fonction immunitaire
EP2473523A2 (fr) 2009-08-31 2012-07-11 Amplimmune, Inc. Méthodes et compositions permettant d'inhiber les rejets de greffe
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
EP2542588A1 (fr) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain et leurs utilisations
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
RS58211B1 (sr) 2010-05-04 2019-03-29 Five Prime Therapeutics Inc Antitela koja vezuju csf1r
KR20210129278A (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
WO2012145568A1 (fr) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Anticorps contre b7x humain pour le traitement du cancer métastatique
LT2703486T (lt) 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2845536A1 (fr) 2011-08-15 2013-02-21 Amplimmune, Inc. Anticorps anti-b7-h4 et leurs utilisations
EP2773651B1 (fr) * 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Compositions spécifiques de b7-h4 isolé et procédés d'utilisation associés
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
KR20150100716A (ko) 2012-12-19 2015-09-02 앰플리뮨, 인크. 항 인간 b7-h4 항체 및 이의 용도
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
WO2014186798A1 (fr) 2013-05-17 2014-11-20 Amplimmune, Inc. Récepteurs pour b7-h4
CA2915665C (fr) 2013-08-01 2020-07-28 Five Prime Therapeutics, Inc. Anticorps anti-fgfr2iiib afucosyles
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2015094782A1 (fr) 2013-12-18 2015-06-25 Albert Einstein College Of Medicine Of Yeshiva University B7x et ses dérivés pour le traitement et la prévention de maladies cardiovasculaires
US20170044268A1 (en) 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
US20170015758A1 (en) 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
US11059898B2 (en) 2014-03-24 2021-07-13 Cancer Research Technology Limited Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
CN103981150B (zh) * 2014-03-28 2016-06-01 苏州大学 抗人b7-h4单克隆抗体及其制备和应用
EP3191518B1 (fr) 2014-09-12 2020-01-15 Genentech, Inc. Anticorps anti-b7-h4 et immunoconjugués
EP3207063B1 (fr) 2014-10-17 2020-12-02 Dana-Farber Cancer Institute, Inc. Méthodes d'identification d'épuisement des lymphocytes t au moyen de modulateurs et de biomarqueurs cd39
EP3223865A4 (fr) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
WO2016160620A2 (fr) 2015-03-27 2016-10-06 University Of Southern California Lymphocytes t car pour le traitement des tumeurs solides exprimant b7-h4
BR112017021688A2 (pt) 2015-04-17 2018-08-14 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
WO2016197204A1 (fr) 2015-06-11 2016-12-15 Bionomics Limited Association pharmaceutique et utilisations de cette association
EP3325512B1 (fr) 2015-07-23 2023-09-06 Inhibrx, Inc. Protéines hybrides multivalentes et multispécifiques se liant à gitr
GEP20227438B (en) 2015-07-30 2022-11-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CA2997217A1 (fr) 2015-09-14 2017-03-23 Alpine Immune Sciences, Inc. Domaines de la superfamille des immunoglobulines a variants accordables et therapie cellulaire mise au point
WO2017058754A1 (fr) 2015-09-28 2017-04-06 Celgene Corporation Multithérapie pour le traitement de cancers hématologiques et de tumeurs solides
EP3371208A1 (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics, Inc. Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
US20190048094A1 (en) 2016-02-24 2019-02-14 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
PL3423087T3 (pl) 2016-03-04 2024-05-20 Io Biotech Aps Skojarzona terapia przeciwnowotworowa
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
FI4019019T3 (fi) 2016-05-20 2024-05-14 Biohaven Therapeutics Ltd Rilutsolin, rilutsolin aihiolääkkeiden tai rilutsolin analogien käyttö immunoterapioiden kanssa syövän hoidossa
AU2017326751A1 (en) 2016-09-16 2019-03-14 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
US10042000B2 (en) 2016-10-13 2018-08-07 Stmicroelectronics (Grenoble 2) Sas Method and apparatus for high frequency analog-to-digital conversion
EP3529361B1 (fr) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Protéines immunomodulatrices sécrétables de type variant et thérapie cellulaire utilisant des cellules obtenues par génie génétique
GB201618291D0 (en) 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
US20230192896A1 (en) 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
CN111094352A (zh) 2017-08-25 2020-05-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法
CA3091161A1 (fr) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. Schemas posologiques d'anticorps b7-h4
EA202091747A1 (ru) 2018-02-21 2021-02-10 Файв Прайм Терапьютикс, Инк. Составы антитела b7-h4
CA3091801A1 (fr) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. Anticorps b7-h4 et leurs procedes d'utilisation
AU2019361923A1 (en) 2018-10-15 2021-06-03 Five Prime Therapeutics, Inc. Combination therapy for cancer

Also Published As

Publication number Publication date
US11939383B2 (en) 2024-03-26
WO2019169212A1 (fr) 2019-09-06
JP2021516051A (ja) 2021-07-01
KR20200144094A (ko) 2020-12-28
CN111971308A (zh) 2020-11-20
SG11202008105RA (en) 2020-09-29
EP3759142A1 (fr) 2021-01-06
CA3091801A1 (fr) 2019-09-06
AU2019228600A1 (en) 2020-09-24
IL276790A (en) 2020-10-29
BR112020017925A2 (pt) 2020-12-22
MX2020009037A (es) 2021-01-08
EA202091810A1 (ru) 2021-01-29
US20210079096A1 (en) 2021-03-18
JP2024026309A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA52416A (fr) Anticorps b7-h4 et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA47691A (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA52203A (fr) Récepteurs chimères pour dll3 et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA53434A (fr) Anticorps anti-tigit
MA46681A (fr) Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
MA52884A (fr) Anticorps anti-il-11
MA49014A (fr) Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
MA48852A (fr) Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation